Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-11-07
CRISPR Therapeutics AG
CRISPR Therapeutics develops CRISPR-based gene and cell therapies, led by CASGEVY with Vertex and a pipeline spanning cardiovascular, autoimmune, oncology, and regenerative programs.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Validated editing platform, breadth still decides value
The company has already proven its core science matters in the real world. The next step is proving that platform credibility can become broader, more directly captured economics rather than a single partner-mediated success.

Analysis

Thesis
CRISPR Therapeutics already cleared the hardest credibility gate with the first approved CRISPR therapy; if it turns that proof into one additional meaningful wholly owned franchise by 2031, the stock can move from cash-backed optionality to a multi-asset gene-editing platform with materially higher revenue and a better multiple.
Last Economy Alignment
AI makes target discovery and design cheaper, but value in this business stays concentrated in scarce trust bottlenecks: human data, IP, manufacturing, and regulatory execution. That is positive for CRISPR Therapeutics, though partner control over CASGEVY limits how much scientific success becomes captured economics.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.4x (from 5 most recent analyses)
Reasoning
The upside case is not that every program works; it is that the company stops being valued mainly as a platform promise and starts being valued as a real franchise builder. CASGEVY can become a durable economic base, while one additional wholly owned program in cardiometabolic disease or cell therapy creates cleaner value capture and a better mix of recurring commercial revenue. That combination supports a meaningful rerating without requiring perfection.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion, not near-term survival. CRISPR Therapeutics has real platform credibility and enough resources to keep taking shots, but the stock still needs broader validation beyond CASGEVY and better direct economic capture from wholly owned assets. Partner concentration, regulatory complexity, and uncertain scaled unit economics are the key reasons the outcome is attractive but still bounded.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.36
They benefit from AI because faster discovery matters, but their real value sits in things AI cannot shortcut: approved human data, manufacturing, and regulator trust. The risk is that their first big win is partly controlled by a partner and newer programs still need to prove they work safely.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$70.83
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case